Skip to main content

Crinetics Pharmaceuticals Inc (CRNX) Stock

Crinetics Pharmaceuticals Inc Stock Details, Movements and Public Alerts

Stock Details

Crinetics Pharmaceuticals Inc (CRNX), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $40.60. Over the past 52 weeks, it has ranged between $24.10 and $62.53. This places the current price at 64.9% of its 52-week high and 68.5% above its 52-week low. Recent trading volume was recorded at 545,451. The 14-day Relative Strength Index (RSI) stands at 44.55, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $39.61 by 2.50%. Similarly, it is above its 200-day moving average of $34.00 by 19.41%. The MACD histogram is -0.41, indicating bearish momentum (MACD Line: 0.60, Signal Line: 1.01). There are currently 3 active alerts set for CRNX by users.

52-Week Range

$62.53 - $24.10

-35.07% from high · +68.46% from low

Avg Daily Volume

1,392,000

20-day average

100-day avg: 1,290,791

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

3.34

EV/EBITDA

-13.40

EPS (TTM)

-$4.10

Price to Sales

2943.00

Beta

0.33

Less volatile than market

How is CRNX valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is CRNX's risk profile compared to the market?
With a beta of 0.33, Crinetics Pharmaceuticals Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 3.34 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-12523.00%

EBITDA

$-419,616,992

Return on Equity

-36.90%

Return on Assets

-23.80%

Revenue Growth (YoY)

158.40%

Earnings Growth (YoY)

0.00%

How profitable and efficient is CRNX's business model?
0 The operating margin of -12523.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -36.90% and ROA at -23.80%, the company achieves moderate returns on invested capital.
What are CRNX's recent growth trends?
Crinetics Pharmaceuticals Inc's revenue grew by 158.40% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$4.1B

Revenue (TTM)

$1.39M

Revenue/Share (TTM)

$0.02

Shares Outstanding

94.18M

Book Value/Share

$12.45

Asset Type

Common Stock

What is CRNX's market capitalization and position?
Crinetics Pharmaceuticals Inc has a market capitalization of $4.1B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 94.18M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does CRNX's price compare to its book value?
Crinetics Pharmaceuticals Inc's book value per share is $12.45, while the current stock price is $40.60, resulting in a price-to-book (P/B) ratio of 3.26. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$80.27

97.71% upside potential

Analyst Recommendations

Strong Buy

5

Buy

10

Hold

2

Sell

0

Strong Sell

0

How reliable are analyst predictions for CRNX?
17 analysts cover CRNX with 88% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $80.27 implies 97.7% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on CRNX?
Current analyst recommendations:5 Strong Buy, 10 Buy, 2 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Nov 2, 2025, 03:12 PM

Technical Indicators

RSI (14-day)

44.55

Neutral

50-Day Moving Average

$39.61

2.50% above MA-50

200-Day Moving Average

$34.00

19.41% above MA-200

MACD Line

0.60

MACD Signal

1.01

MACD Histogram

-0.41

Bearish

What does CRNX's RSI value tell investors?
The RSI (Relative Strength Index) for CRNX is currently 44.55, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this shows mixed signals requiring careful analysis.
How should traders interpret CRNX's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.60 below the signal line at 1.01, with histogram at -0.41. This bearish crossover indicates downward pressure. The 50-day MA ($39.61) is above the 200-day MA ($34.00), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Nov 10, 2025, 09:01 AM

Active Alerts

Alert Condition
Price falls below
Threshold
$38.00
Created
Nov 10, 2025, 02:13 PM
Alert Condition
RSI Threshold Cross
Threshold
40
Created
Nov 10, 2025, 02:13 PM
Alert Condition
MA Breakout (Bearish)
Threshold
50 days
Created
Nov 10, 2025, 02:13 PM

Stay Ahead of the Market with Crinetics Pharmaceuticals Inc Alerts

Set up price alerts for Crinetics Pharmaceuticals Inc and get notified instantly when the price hits your target. Never miss an important price movement again.